Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
selpercatinib save search
Lilly's Retevmo® (selpercatinib) Phase 3 Results in RET Fusion-Positive Non-Small Cell Lung Cancer and RET-Mutant Medullary Thyroid Cancer Both Published in The New England Journal of Medicine and Presented in a Presidential Symposium at ESMO Congress 2023
Published: 2023-10-21 (Crawled : 16:20) - prnewswire.com
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
| Email alert
Add to watchlist
retevmo lung congress symposium cancer cell thyroid results
U.S. Food and Drug Administration (FDA) Approves FoundationOne®CDx as a Companion Diagnostic for Lilly’s Retevmo® (selpercatinib) for Certain Patients with Solid Tumors
Published: 2023-10-09 (Crawled : 18:00) - biospace.com/
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -0.21%
H: 2.8%
C: 1.37%
foundationone drug diagnostic food tumors companion
Lilly's Retevmo® (selpercatinib) Demonstrates Superior Progression-Free Survival Compared to Approved Multikinase Inhibitors in RET-Mutant Medullary Thyroid Cancer
Published: 2023-08-22 (Crawled : 12:20) - biospace.com/
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.3%
H: 1.19%
C: 0.75%
retevmo approved cancer thyroid
Lilly's Retevmo® (selpercatinib) is the First Targeted Therapy to Demonstrate Superior Progression-Free Survival Compared to a PD-1 Inhibitor Plus Chemotherapy
Published: 2023-08-04 (Crawled : 12:00) - biospace.com/
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -0.53%
H: 0.0%
C: 0.0%
retevmo plus therapy
The China NMPA Approves Selpercatinib for the Treatment of Patients with RET-driven Lung and Thyroid Cancers
Published: 2022-10-10 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
|
| O: -0.1%
H: 0.0%
C: 0.0%
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -0.13%
H: 0.24%
C: -0.72%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: -0.82%
H: 0.0%
C: 0.0%
INCY | $52.74 -0.9% -0.91% 2.5M
|
Health Technology
|
| O: 0.2%
H: 0.1%
C: -1.43%
treatment lung thyroid china
FDA Approves Lilly's Retevmo® (selpercatinib), the First and Only RET Inhibitor for Adults with Advanced or Metastatic Solid Tumors with a RET Gene Fusion, Regardless of Type
Published: 2022-09-21 (Crawled : 00:00) - prnewswire.com
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 1.46%
H: 3.93%
C: 3.35%
retevmo fda
Lilly Presents Updated Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Non-Small-Cell Lung Cancer (NSCLC) at the 2022 European Lung Cancer Congress
Published: 2022-04-01 (Crawled : 11:00) - prnewswire.com
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -0.08%
H: 2.44%
C: 2.28%
retevmo cancer
FDA approves selpercatinib for lung and thyroid cancers with RET gene mutations or fusions
Published: 2021-06-11 (Crawled : 18:17) - fda.gov
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
| Email alert
Add to watchlist
fda fda approval cancer
Lilly Presents New Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Gastrointestinal and Other Cancers at 2021 American Association for Cancer Research (AACR) Annual Meeting
Published: 2021-04-11 (Crawled : 20:20) - prnewswire.com
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -0.57%
H: 0.28%
C: -0.88%
test positive cancer gastrointestinal research
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.